Basic information Side effects Small Molecule Inhibitor FDA Approve Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Regorafenib

Regorafenib

Basic information Side effects Small Molecule Inhibitor FDA Approve Safety Related Supplier
Regorafenib Basic information
Regorafenib Chemical Properties
  • Melting point:206.0 to 210.0 °C
  • Boiling point:513.4±50.0 °C(Predicted)
  • Density 1.491±0.06 g/cm3(Predicted)
  • form White powder.
  • pka12.04±0.70(Predicted)
  • CAS DataBase Reference755037-03-7
Safety Information
  • HS Code 29242990
Regorafenib Usage And Synthesis
  • Side effects

    Regorafenib is being approved with a Boxed Warning alerting patients and health care professionals that severe and fatal liver toxicity occurred in patients treated with regorafenib during clinical studies. Serious side effects, which occurred in less than one percent of patients, were liver damage, severe bleeding, blistering and peeling of skin, very high blood pressures requiring emergency treatment, heart attacks and perforations (holes) in the intestines. The most common side effects reported in patients treated with regorafenib include weakness or fatigue, loss of appetite, hand-foot syndrome (also called palmar-plantar erythrodysesthesia), diarrhoea, mouth sores (mucositis), weight loss, infection, high blood pressure, and changes in voice volume or quality (dysphonia).

  • Small Molecule Inhibitor

    Regorafenib (BAY 73-4506, Stivarga ) is a new oral small molecule multi-kinases inhibitor. It can inhibit the target kinases associated with angiogenesis and tumorigenesis. The pathway influenced by regorafenib and the biomarkers for monitoring the efficacy of regorafenib become hot spots. Because of its wide spectrum kinase inhibitory activity, the utilization of regorafenib in many clinical indications are also carried out extensively. Since regorafenib is approved with the box warning, its side effects can not be ignored.

  • FDA Approve

    Regorafenib (BAY73-4506) is a new type of multikinase inhibitor developed by Bayer, and is the first small molecule kinase inhibitor approved by the U.S. FDA on September 27, 2012 used for fast track colorectal cancer that develops and metastases after conventional treatment. 
    Regorafenib achieves good results in some patients with rectal cancer that are resistant to traditional chemotherapy, but not all rectal cancers are sensitive to it. Therefore, the pathway influenced by regorafenib and the biomarkers for monitoring the efficacy of regorafenib become hot spots.

  • DescriptionIn September 2012, theUSFDAapproved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC), especially those for whom standard therapies have failed, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, ananti-EGFRtherapy. Regorafenib is a multikinase inhibitor with potent inhibitory activity versus VEGFRs and PDFRs. Both of these classes of receptors are expressed on tumor cells and affect proliferation and angiogenesis. Regorafenib inhibited growth in murine xenograft models for colon, breast, renal, lung, melanoma, pancreatic, and ovarian tumors when dosed at 10–30 mg/kg. Regorafenib is a fluorinated analog of sorafenib, a multikinase inhibitor co-marketed by Bayer and Onyx for the treatment of kidney and liver cancer. The synthesis of regorafenib is accomplished in two steps from commercially available starting materials. 4-Aminophenol is coupled to 4-chloro-N-methyl- 2-pyridinecarboxamide to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. Subsequent treatment with 4-chloro-3-(trifluoromethyl)phenyl isocycanate affords the urea, regorafenib.
  • OriginatorBayer (Germany)
  • UsesIt inhibits PDGFR tyrosine kinase with IC50=83nM. It is useful for the treatment of inflammation and as an anti-proliferative agent.
  • UsesBAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.
  • UsesRegorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively
  • DefinitionChEBI: A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previ usly received chemotherapy, anti-EGFR or anti-VEGF therapy.
  • brand nameStivarga
Regorafenib(755037-03-7)Related Product Information
RegorafenibSupplierMore
  • Company Name:Yangzhou QinYuan Pharmaceutical Co., Ltd. Gold
  • Tel:13773367191 0514-80939770
  • Email:yzqyyykj@163.com
  •  
  • Company Name:Taizhou KEDE Chemical Co., Ltd Gold
  • Tel:13093829633
  • Email:sales@kedechemical.com;sales01@kedechemical.com;
  •  
  • Company Name:Shandong Haiwo Biological Technology Co., Ltd. Gold
  • Tel:13046003282 0531-87586188-
  • Email:sales@hwbiology.com
  •  
  • Company Name:Beijing Sai Siyuan Biomedical Technology Co., Ltd. Gold
  • Tel:13522399152 010-87925700-
  • Email:1664478984@qq.com
  •  
  • Company Name:Wuhan Chemprospect Pharmaceutical Co., Ltd. Gold
  • Tel:13971349987
  • Email:sale@chemprospect.com;
  •  
Related articles